Teva Pharmaceutical Industries (NYSE:TEVA) Price Target Raised to $26.00

Key Points

• Teva Pharmaceutical Industries has had its price target raised by JPMorgan Chase & Co. to $26.00, indicating a potential upside of 29.68% from its current price.
• Analysts are generally optimistic, with a consensus rating of "Buy" and an average price target of $25.57 for the company.
• Despite a recent stock performance dip of 0.1%, Teva reported earnings per share of $0.66, exceeding analysts' estimates, and had a revenue of $4.18 billion for the last quarter.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) had its price objective upped by equities researchers at JPMorgan Chase & Co. from $23.00 to $26.00 in a research note issued on Friday,Benzinga reports. The firm currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price points to a potential upside of 29.68% from the stock's current price.

Several other research analysts also recently issued reports on TEVA. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Saturday, July 26th. The Goldman Sachs Group began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price objective for the company. Finally, UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, September 24th. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of "Buy" and an average price target of $25.57.

Teva Pharmaceutical Industries Stock Down 0.1%

TEVA opened at $20.05 on Friday. The firm has a 50 day moving average price of $18.05 and a 200 day moving average price of $16.79. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a market cap of $23.00 billion, a PE ratio of -125.31, a price-to-earnings-growth ratio of 1.17 and a beta of 0.71. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion during the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. Teva Pharmaceutical Industries's revenue was up .3% on a year-over-year basis. During the same period in the previous year, the business posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Sell-side analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Placid Jover sold 6,053 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the sale, the insider owned 6,774 shares in the company, valued at $102,693.84. This represents a 47.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. Company insiders own 0.49% of the company's stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several large investors have recently added to or reduced their stakes in TEVA. Duquesne Family Office LLC grew its position in Teva Pharmaceutical Industries by 65.4% during the first quarter. Duquesne Family Office LLC now owns 14,879,750 shares of the company's stock valued at $228,702,000 after buying an additional 5,882,350 shares during the period. Amundi raised its stake in shares of Teva Pharmaceutical Industries by 18.5% during the first quarter. Amundi now owns 678,758 shares of the company's stock valued at $10,080,000 after acquiring an additional 105,846 shares during the last quarter. IFM Investors Pty Ltd lifted its holdings in Teva Pharmaceutical Industries by 9.4% in the second quarter. IFM Investors Pty Ltd now owns 226,534 shares of the company's stock worth $3,797,000 after buying an additional 19,447 shares during the period. Bourgeon Capital Management LLC raised its stake in Teva Pharmaceutical Industries by 100.7% during the second quarter. Bourgeon Capital Management LLC now owns 723,974 shares of the company's stock valued at $12,134,000 after buying an additional 363,252 shares during the last quarter. Finally, Jump Financial LLC lifted its holdings in shares of Teva Pharmaceutical Industries by 172.1% during the first quarter. Jump Financial LLC now owns 1,325,526 shares of the company's stock valued at $20,373,000 after purchasing an additional 838,423 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.